ValuEngine upgraded shares of Trxade Group (OTCMKTS:TRXD) from a sell rating to a hold rating in a research report released on Thursday morning.
TRXD has been the topic of several other reports. Taglich Brothers reiterated a speculative buy rating on shares of Trxade Group in a research report on Friday, October 6th. Zacks Investment Research upgraded Trxade Group from a hold rating to a buy rating and set a $0.25 price target on the stock in a research report on Thursday, December 7th.
Trxade Group (OTCMKTS TRXD) opened at $0.45 on Thursday. The company has a debt-to-equity ratio of -0.82, a quick ratio of 0.85 and a current ratio of 0.85. Trxade Group has a 1 year low of $0.22 and a 1 year high of $1.00.
ILLEGAL ACTIVITY NOTICE: This article was first published by Equities Focus and is owned by of Equities Focus. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.equitiesfocus.com/2018/01/08/valuengine-upgrades-trxade-group-trxd-to-hold.html.
Trxade Group Company Profile
Trxade Group, Inc (Trxade) designs, develops, owns and operates a business-to-business Web-based marketplace focused on the United States pharmaceutical industry. The Company’s products and services include Trxade.com, InventoryRx.com, Pharmabayonline and RxGuru. Its services are distributed through its online platform.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Trxade Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trxade Group and related companies with MarketBeat.com's FREE daily email newsletter.